https://ntp.niehs.nih.gov/go/18981

Diisopropylcarbodiimide: Target Organs and Levels of Evidence for GMM-10

Toxicology Study of Diispropylcarbodiimide (CASRN 693-13-0) in Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Diispropylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Diisopropylcarbodiimide
693-13-0		 09/28/2005 Topical Application
Female Mice: 0, 4.38, 8.75, 17.5, 35, or 70 mg/kg; 10/group		 BioReliance, Inc
Levels of evidence information forToxicology Study of Diisopropylcarbodiimide in Female Tg.AC Hemizygous Mice
  Female Tg.AC Hemizygous Mice
  20 Weeks
Neoplastic Lesions None
Non-Neoplastic Lesions None



Levels of evidence information forCarcinogenesis Study of Diisopropylcarbodiimide in Female p53 Haploinsufficient Mice
  Female p53 Haploinsufficient Mice
  27 Weeks
Levels of Evidence No Evidence
Neoplastic Lesions None
Non-Neoplastic Lesions
  • Skin: epidermal hyperplasia